Quintiles is reporting the launch of Kun Tuo, a contract research organization (CRO) based in China. It has been established to service the needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.
Quintiles has had much CRO success at the global level. It has reportedly been conducting clinical trials in China since 1997. Kun Tuo will tap into this expertise and resources, with a focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China.
Kun Tuo will provide a full range of services including clinical trial management, regulatory submission preparation, biostatistics, and data management. It will develop customized offerings in key therapeutic areas along with vaccines, late-phase studies, medical devices, and diagnostics.
“Kun Tuo will leverage Quintiles’ quality and training systems to offer customized, high-quality solutions best suited for local Chinese biopharma as well as global biopharma local affiliates,” said Ling Zhen, GM, Quintiles China. “We have an aggressive growth plan for China and anticipate doubling Quintiles total staff during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world’s most dynamic marketplaces.” Quintiles China today has more than 300 staff to cover all population centers and study sites in China.